Logo

American Heart Association

  2
  0


Final ID: Sa1021

Trends in Statin Use for the Secondary Prevention of Atherosclerotic Cardiovascular Disease among U.S. Adults by Age, 1999-2020

Abstract Body (Do not enter title and authors here): BackGround
Current research focusing on trends in statin medication usage, particularly for different age groups, is limited. This study explored the change trends in statin usage from 1999 to 2020, with a specific focus on different age groups.
Methods
Utilizing data from the National Health and Nutrition Examination Survey spanning the period from 1999 to 2020, our study included individuals aged 18 years and older diagnosed with atherosclerotic cardiovascular disease (ASCVD).
Results
In the 18-44 years age group, usage changed from 18.34% (95% CI, 0.18 to 36.50) in 1999 to 16.63% (95% CI, 0.36 to 32.91) in 2020 (linear P value = 0.540, quadratic P value = 0.610) (Figure 1). For individuals aged 45-64 years, usage increased from 39.33% (95% CI, 29.62 to 49.05) in 1999 to 54.97% (95% CI, 47.10 to 662.83) in 2020 (linear P value < 0.001, quadratic P value = 0.777) (Figure 1). In the group aged 65 years and older, usage increased from 35.17% (95% CI, 29.57 to 40.77) in 1999 to 60.62% (95% CI, 55.73 to 65.51) in 2010, and further to 68.62% (95% CI, 63.65 to 73.60) in 2020 (quadratic P value < 0.001) (Figure 1). There was an interaction effect between statin usage trends and age (P for interaction <0.001) (Figure 1).

Conclusion
Overall, current health policies are effective for the use of statins for the secondary prevention of ASCVD. However, there was almost no improvement in statin usage within the 18-44 years age group. This highlights the need for greater focus on young ASCVD patients. Therefore, additional research is needed on statin use among young people.
  • Junwen, Wang  ( West China Hosptal,Sichuan University , Chengdu , Sichuan , China )
  • Ye, Yuyang  ( West China Hosptal,Sichuan University , Chengdu , Sichuan , China )
  • Chen, Xuefeng  ( West China Hosptal,Sichuan University , Chengdu , Sichuan , China )
  • Hu, Xinru  ( West China Hosptal,Sichuan University , Chengdu , Sichuan , China )
  • Peng, Yong  ( West China Hosptal,Sichuan University , Chengdu , Sichuan , China )
  • Author Disclosures:
    Wang Junwen: DO NOT have relevant financial relationships | Yuyang YE: No Answer | Xuefeng CHEN: No Answer | Xinru HU: No Answer | Yong Peng: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Lipoproteins - Clinical and Translational Studies

Saturday, 11/16/2024 , 10:30AM - 11:30AM

Abstract Poster Session

More abstracts on this topic:
Clinical Outcomes of GLP-1 RA in Heart Failure with CKD patients: A TriNetX Based Global Study

Hanif Muhammad, Islam Sabeeh, Singh Sumi, Ochani Rohan Kumar, Yasmin Farah, Jha Mayank, Chaudhuri Debanik, Jaiswal Vikash, Bhandari Jenish, Ali Junaid, Devakumar Sahana, Ishaq Muhammad, Sundas Fnu, Yousaf Hamza, Khan Arshan

Efficacy and Safety of Empagliflozin after Acute Myocardial Infarction: A Systematic Review and Meta Analysis

Otmani Zina, Yassin Mazen Negmeldin Aly, Ayman Elsayed Hazem, Alahmed Farouq, Al Zoubi Bashar M., Hany Mohammed Omar, Belakhdar Abdelbassat, K. Awad Ahmed

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available